Fairmont Banff Springs Floorplan

Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2014
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
HIV Pathogenesis - Virus vs. Host (X4)
Organizer(s) J. Victor Garcia-Martinez, Daria J. Hazuda and Dan R. Littman
March 9—14, 2014
Fairmont Banff Springs • Banff, AB Canada
Discounted Abstract Deadline: Nov 7, 2013
Abstract Deadline: Dec 11, 2013
Scholarship Deadline: Nov 7, 2013
Discounted Registration Deadline: Jan 10, 2014
Sponsored by Gilead Sciences, Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
Joint Meeting:
HIV Vaccines: Adaptive Immunity and Beyond (X3)
Summary of Meeting:
This meeting is focused on the latest breakthroughs in basic and translational HIV research with an emphasis on mechanistic models. It presents a detailed tour of all the key steps of virus replication from infection to AIDS. The program seamlessly incorporates key aspects of HIV biology including: 1) Virus entry/exit into/from the cell; 2) Entry into the host; 3) Virus-host genetics and co-evolution; 4) Virus-host interactions and responses; 5) Pathogenesis; 6) Reservoirs, latency and reactivation; and 7) HIV and the microbiome at the mucosa. Strong emphasis will be given to these and other areas well represented in the abstracts submitted. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on “HIV Vaccines: Adaptive Immunity and Beyond,” which shares opening and closing keynote addresses and two plenary sessions with this meeting.
View Scholarships/Awards
This meeting is focused on the latest breakthroughs in basic and translational HIV research with an emphasis on mechanistic models. It presents a detailed tour of all the key steps of virus replication from infection to AIDS. The program seamlessly incorporates key aspects of HIV biology including: 1) Virus entry/exit into/from the cell; 2) Entry into the host; 3) Virus-host genetics and co-evolution; 4) Virus-host interactions and responses; 5) Pathogenesis; 6) Reservoirs, latency and reactivation; and 7) HIV and the microbiome at the mucosa. Strong emphasis will be given to these and other areas well represented in the abstracts submitted. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on “HIV Vaccines: Adaptive Immunity and Beyond,” which shares opening and closing keynote addresses and two plenary sessions with this meeting.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, MARCH 9
MONDAY, MARCH 10
TUESDAY, MARCH 11
WEDNESDAY, MARCH 12
THURSDAY, MARCH 13
FRIDAY, MARCH 14
Conference Program Print | View meeting in 12 hr (am/pm) time
SUNDAY, MARCH 9
16:30—18:00
Keystone Symposia Webcast - HIV/AIDS: Strategies for an Endgame
Taped rebroadcast of the first virtual Keystone Symposia event. This can also be viewed online at any time at www.visualwebcaster.com/KSHIV.
08:00—09:00
Opening Addresses (Joint)
*
Nicole Frahm,
Bill & Melinda Gates Medical Research Institute, USA
*
J. Victor Garcia-Martinez,
University of North Carolina at Chapel Hill, USA
Myron S. Cohen,
University of North Carolina at Chapel Hill, USA
Integrated HIV Prevention Strategies: High Time for a Synergistic Approach
Integrated HIV Prevention Strategies: High Time for a Synergistic Approach
Carl W. Dieffenbach,
NIAID, National Institutes of Health, USA
The Big Questions: The Basic Research Progress Needed to Help Control the HIV/AIDS Pandemic
The Big Questions: The Basic Research Progress Needed to Help Control the HIV/AIDS Pandemic
09:00—11:30
Portals of Entry and Sites of Dissemination (Joint)
*
James A. Hoxie,
University of Pennsylvania, USA
*
Thomas Musich,
Armed Forces Research Institute of Medical Sciences, Thailand
J. Victor Garcia-Martinez,
University of North Carolina at Chapel Hill, USA
Mechanistic Analysis of Vaginal HIV Transmission and Prevention
Mechanistic Analysis of Vaginal HIV Transmission and Prevention
Ashley T. Haase,
University of Minnesota, USA
Virus-Host Immune Interactions at the Portal of Entry and Vaccine Design to Prevent HIV-1 Transmission to Women
Virus-Host Immune Interactions at the Portal of Entry and Vaccine Design to Prevent HIV-1 Transmission to Women
Thomas J. Hope,
Northwestern University, USA
Short Talk: Hotspots of SIV Infection in the Female Reproductive Tract after Vaginal Exposure of Rhesus macaques to Single Round Dual Reporter Vector
Short Talk: Hotspots of SIV Infection in the Female Reproductive Tract after Vaginal Exposure of Rhesus macaques to Single Round Dual Reporter Vector
Samuel K. Lai,
University of North Carolina at Chapel Hill, USA
Short Talk: Influence of Vaginal Microbiota on the Diffusional Barrier Properties of Cervicovaginal Mucus against HIV
Short Talk: Influence of Vaginal Microbiota on the Diffusional Barrier Properties of Cervicovaginal Mucus against HIV
14:30—16:30
Workshop 1: Role of Animal Models for HIV Research
*
Roberto F. Speck,
University of Zurich, Switzerland
*
Frank Kirchhoff,
University of Ulm, Germany
Atef F. Allam,
Walter Reed Institute of Research, USA
Characterization of B- and T Cells in the Gut Mucosa of Humanized DRAG Mice During HIV Infection
Characterization of B- and T Cells in the Gut Mucosa of Humanized DRAG Mice During HIV Infection
Timothy E. Dudek,
Ragon Institute of MGH, MIT and Harvard, USA
Immunization of Humanized BLT Mice Against HIV Influences Early Immune Responses and Viral Loads
Immunization of Humanized BLT Mice Against HIV Influences Early Immune Responses and Viral Loads
Yanhui Cai,
Tulane National Primate Research Center, USA
SIV Infection of Lung Interstitial Macrophages Contributes to Tissue Damage and Inflammatory Responses in the Lung
SIV Infection of Lung Interstitial Macrophages Contributes to Tissue Damage and Inflammatory Responses in the Lung
Christopher A. Gaulke,
University of California, Davis, USA
SIV Induced Disruption of microRNA Expression in the Small Intestine Contributes to Epithelial Barrier Dysfunction
SIV Induced Disruption of microRNA Expression in the Small Intestine Contributes to Epithelial Barrier Dysfunction
Jung Joo Hong,
Korea Research Institute of Bioscience and Biotechnology, South Korea
Early Lymphoid Responses and Germinal Center Formation Correlates with Lower Viral Load Set Points and Better Prognosis of SIV Infection
Early Lymphoid Responses and Germinal Center Formation Correlates with Lower Viral Load Set Points and Better Prognosis of SIV Infection
Luca Micci,
Emory University, YNPRC, USA
Interleukin-21 Reduces Residual Immune Activation in ART-Suppressed SIV-Infected Rhesus macaques by Restoring Intestinal Th17 and Th22 Cells
Interleukin-21 Reduces Residual Immune Activation in ART-Suppressed SIV-Infected Rhesus macaques by Restoring Intestinal Th17 and Th22 Cells
M. Christine Zink,
Johns Hopkins University, USA
Sustained Upregulation of Neurotoxic Kynurenine Pathway Metabolites in cART-Treated SIV-Infected Pigtailed Macaques: Impact on Neuroinflammation and Serotonin Metabolism
Sustained Upregulation of Neurotoxic Kynurenine Pathway Metabolites in cART-Treated SIV-Infected Pigtailed Macaques: Impact on Neuroinflammation and Serotonin Metabolism
Adrienne E. Swanstrom,
University of Pennsylvania, USA
In Vivo Evaluation of a Novel Variant of SIVmac Lacking CD4 Tropism
In Vivo Evaluation of a Novel Variant of SIVmac Lacking CD4 Tropism
14:30—16:30
Workshop 1: Mucosal Immunity
*
Marjorie Robert-Guroff,
NCI, National Institutes of Health, USA
*
Thomas J. Hope,
Northwestern University, USA
Liang Shang,
University of Minnesota, USA
Immune Complex – Fc Receptor Interactions Reduce Inflammatory Responses at the Genital Mucosa as a Correlate of SIV Vaccine-Induced Protection
Immune Complex – Fc Receptor Interactions Reduce Inflammatory Responses at the Genital Mucosa as a Correlate of SIV Vaccine-Induced Protection
Yichuan Wang,
NCI, National institutes of Health, USA
Vaginal Type-II Mucosa Acts as an Inductive Site for the Generation of Primary CD8+ T Cell Mucosal Immune Responses
Vaginal Type-II Mucosa Acts as an Inductive Site for the Generation of Primary CD8+ T Cell Mucosal Immune Responses
Genoveffa Franchini,
NCI, National Institutes of Health, USA
Modulation of the RAS Pathways as a Biomarker of Protection Against HIV and as a Means to Improve Vaccine Efficacy
Modulation of the RAS Pathways as a Biomarker of Protection Against HIV and as a Means to Improve Vaccine Efficacy
Rena D. Astronomo,
Fred Hutchinson Cancer Research Center, USA
Neutrophils May Provide Front-Line Antibody Effector Functions in the Cervical But Not the Vaginal Mucosa
Neutrophils May Provide Front-Line Antibody Effector Functions in the Cervical But Not the Vaginal Mucosa
Béhazine Combadiere,
Centre d'Immunologie et des Maladies Infectieuses, France
Cutaneous Routes for HIV Vaccination Strategies
Cutaneous Routes for HIV Vaccination Strategies
Sampa Santra,
Harvard Medical School, USA
Simian-Human Immunodeficiency Viruses with Transmitted/Founder Clade C HIV-1 Envelopes
Simian-Human Immunodeficiency Viruses with Transmitted/Founder Clade C HIV-1 Envelopes
Thorsten Demberg,
NCI, National Institutes of Health, USA
Phenotyping and Characterization of Mucosal Memory B-Cell Populations in the SIV/SHIV Rhesus macaque Model
Phenotyping and Characterization of Mucosal Memory B-Cell Populations in the SIV/SHIV Rhesus macaque Model
Thomas Musich,
Armed Forces Research Institute of Medical Sciences, Thailand
Purification and Functional Characterization of Mucosal IgA from Vaccinated and SIV-Infected Rhesus macaques
Purification and Functional Characterization of Mucosal IgA from Vaccinated and SIV-Infected Rhesus macaques
15:30—17:00
Keystone Symposia Webcast - HIV/AIDS: Strategies for an Endgame
Taped rebroadcast of the first virtual Keystone Symposia event. This can also be viewed online at any time at www.visualwebcaster.com/KSHIV.
15:30—17:00
Keystone Symposia Webcast - HIV/AIDS: Strategies for an Endgame
Taped rebroadcast of the first virtual Keystone Symposia event. This can also be viewed online at any time at www.visualwebcaster.com/KSHIV.
17:00—19:15
Host-Viral Co-Evolution
*
Quentin J. Sattentau,
Sir William Dunn School of Pathology, UK
*
Doris Wilflingseder,
Insbruck Medical University, Austria
Welkin E. Johnson,
Boston College, USA
Genetic Barriers to Cross-Species Transmission and Emergence of Primate Immunodeficiency Viruses
Genetic Barriers to Cross-Species Transmission and Emergence of Primate Immunodeficiency Viruses
Robert J. Gifford,
University of Glasgow, UK
The Evolution and Emergence of Lentiviral Pandemics since the Neolithic Era
The Evolution and Emergence of Lentiviral Pandemics since the Neolithic Era
Viviana Simon,
Icahn School of Medicine at Mount Sinai, USA
Short Talk: HIV Evolution in Humanized Mice
Short Talk: HIV Evolution in Humanized Mice
Li Wu,
Ohio State University, USA
Short Talk: Identification of Cellular Proteins Interacting with the Retroviral Restriction Factor SAMHD1
Short Talk: Identification of Cellular Proteins Interacting with the Retroviral Restriction Factor SAMHD1
Thijs Booiman,
University of Amsterdam, Netherlands
Short Talk: The Effect of Genetic Variation in Trex1 on HIV-1 Disease Progression and in vitro HIV-1 Replication
Short Talk: The Effect of Genetic Variation in Trex1 on HIV-1 Disease Progression and in vitro HIV-1 Replication
Angelique Hoelzemer,
Ragon Institute of MGH, MIT and Harvard, USA
Short Talk: Selection of a Distinct HIV-1 p24 Gag Sequence Polymorphism in KIR2DL3/HLA-C*03:04+ Individuals Is Associated with Viral Escape from Recognition by KIR2DL3+ NK Cells
Short Talk: Selection of a Distinct HIV-1 p24 Gag Sequence Polymorphism in KIR2DL3/HLA-C*03:04+ Individuals Is Associated with Viral Escape from Recognition by KIR2DL3+ NK Cells
17:00—19:15
Programming Durable Immunity
*
Rafael Cubas,
Genentech, USA
*
Hendrik Streeck,
Military HIV Research Program, USA
Robert A. Seder,
NIAID, National Institutes of Health, USA
Development of a Malaria Vaccine: A Parable of Vaccine Delivery, Breadth of Antigens and Effector Cells
Development of a Malaria Vaccine: A Parable of Vaccine Delivery, Breadth of Antigens and Effector Cells
Mark K. Slifka,
Oregon National Primate Research Center, Oregon Health & Science University, USA
Potential Mechanisms for Sustaining Long-Term Humoral Immunity
Potential Mechanisms for Sustaining Long-Term Humoral Immunity
Shane Crotty,
La Jolla Institute for Immunology, USA
Tfh Cells and Memory Tfh Cells
Tfh Cells and Memory Tfh Cells
Diego J. Farfán-Arribas,
University of Massachusetts Medical School, USA
Short Talk: Evidence on the Involvement of Germinal Centers and T Follicular Helper Cells in DNA Immunization for HIV Vaccine Development
Short Talk: Evidence on the Involvement of Germinal Centers and T Follicular Helper Cells in DNA Immunization for HIV Vaccine Development
Ann J. Hessell,
Oregon Health & Science University, USA
Short Talk: Cross-Clade Neutralizing Antibodies and Envelope-Specific TFH Cell Responses Are Elicited in Macaques Co-Immunized with DNA and Protein Env Vaccines Derived from Multiple Subjects during Development of Breadth
Short Talk: Cross-Clade Neutralizing Antibodies and Envelope-Specific TFH Cell Responses Are Elicited in Macaques Co-Immunized with DNA and Protein Env Vaccines Derived from Multiple Subjects during Development of Breadth
08:00—11:15
Viral Entry/Exit and Host Genetics
*
Eric Hunter,
Emory University, USA
*
Gilda Tachedjian,
Burnet Institute, Australia
Wesley I. Sundquist,
University of Utah School of Medicine, USA
HIV Assembly and Egress
HIV Assembly and Egress
Vineet N. KewalRamani,
NCI, National Institutes of Health, USA
HIV Entry and Nuclear Translocation
HIV Entry and Nuclear Translocation
Fadila Bouamr,
NIAID, National Institutes of Health, USA
The Host and HIV Exit
The Host and HIV Exit
Janice E. Clements,
Johns Hopkins University, USA
Macrophages Contribute to the Latent Viral Reservoir in Tissues of cART Suppressed SIV-Infected Macaques
Macrophages Contribute to the Latent Viral Reservoir in Tissues of cART Suppressed SIV-Infected Macaques
Peijun Zhang,
University of Oxford, UK
Short Talk: Structural Mechanisms of HIV-1 Capsid Assembly and Maturation
Short Talk: Structural Mechanisms of HIV-1 Capsid Assembly and Maturation
Amy Hulme,
Northwestern University, USA
Short Talk: Viral and Cellular Factors Affect HIV-1 Uncoating
Short Talk: Viral and Cellular Factors Affect HIV-1 Uncoating
08:00—11:00
Inducing Protective Immunity
*
Anne-Sophie M. Dugast,
Ragon Institute of MGH, MIT and Harvard, USA
*
Adrian B. McDermott,
National Institutes of Health, USA
Gabriel D. Victora,
Rockefeller University, USA
Cellular Dynamics and Clonal Selection in the Germinal Center
Cellular Dynamics and Clonal Selection in the Germinal Center
Jonathan W. Yewdell,
NIAID, National Institutes of Health, USA
Translating Information for MHC Class Immunosurveillance
Translating Information for MHC Class Immunosurveillance
Susan W. Barnett,
Bill & Melinda Gates Foundation, USA
Non-Viral Delivery of Self-Amplifying mRNA: A Versatile Synthetic Vaccine Platform for HIV
Non-Viral Delivery of Self-Amplifying mRNA: A Versatile Synthetic Vaccine Platform for HIV
Kelly D. Moynihan,
Third Rock Ventures, USA
Short Talk: Lymph-Node Targeting of Molecular Vaccines through “Albumin Hitchhiking”
Short Talk: Lymph-Node Targeting of Molecular Vaccines through “Albumin Hitchhiking”
Joseph G. Jardine,
The Scripps Research Institute, USA
Short Talk: Design of Germline-Targeted Immunogens with Enhanced Breadth for VRC01-Class Precursors
Short Talk: Design of Germline-Targeted Immunogens with Enhanced Breadth for VRC01-Class Precursors
14:30—16:30
Panel 1: HIV/AIDS: Strategies for an Endgame (Joint)
*
Carl W. Dieffenbach,
NIAID, National Institutes of Health, USA
Galit Alter,
MIT and Harvard University, USA
Peter A. Anton,
David Geffen School of Medicine at UCLA, USA
Myron S. Cohen,
University of North Carolina at Chapel Hill, USA
Magdalena E. Sobieszczyk,
Columbia University, USA
David M. Margolis,
University of North Carolina at Chapel Hill, USA
Thomas C. Quinn,
NIAID and Johns Hopkins University, USA
17:00—19:00
Mechanistic Models of Pathogenesis and Disease
*
Heinrich Gottlinger,
University of Massachusetts Medical School, USA
*
Shokrollah Elahi,
University of Alberta, Canada
Richard T. D'Aquila,
Northwestern University, USA
APOBEC3s versus Vif-Positive HIV-1: Tipping the Balance toward Virus Control
APOBEC3s versus Vif-Positive HIV-1: Tipping the Balance toward Virus Control
Timothy W. Schacker,
University of Minnesota, USA
The Natural History of HIV Infection in Lymphatic Tissues
The Natural History of HIV Infection in Lymphatic Tissues
Anthony L. Cunningham,
Westmead Institute for Medical Research, Australia
Short Talk: HIV Inhibits Interferon Production in Macrophages and Dendritic Cells but Exerts Other Antiviral Mechanisms
Short Talk: HIV Inhibits Interferon Production in Macrophages and Dendritic Cells but Exerts Other Antiviral Mechanisms
Anna Aldovini,
Boston Children's Hospital and Harvard Medical School, USA
Short Talk: HIV-1 Tat Engagement of Different Promoters in Different Cell Types Results in Apoptosis of CD4+ T Cells and Activation of ISG Linked to Immune Activation in Antigen Presenting Cells
Short Talk: HIV-1 Tat Engagement of Different Promoters in Different Cell Types Results in Apoptosis of CD4+ T Cells and Activation of ISG Linked to Immune Activation in Antigen Presenting Cells
17:00—19:15
Tackling Global HIV Diversity
*
Richard A. Koup,
NIAID, National Institutes of Health, USA
*
Edward A. Berger,
NIAID, National Institutes of Health, USA
Beatrice H. Hahn,
University of Pennsylvania, USA
Phenotypic Properties of Transmitted Founder HIV-1
Phenotypic Properties of Transmitted Founder HIV-1
Bette Tina Marie Korber,
Los Alamos National Laboratory, USA
Using Signatures of Neutralizing Antibodies to Inform Vaccine Design
Using Signatures of Neutralizing Antibodies to Inform Vaccine Design
Andrew B. Ward,
The Scripps Research Institute, USA
High-Resolution Cryo-EM Studies of HIV-1 Env
High-Resolution Cryo-EM Studies of HIV-1 Env
Dan H. Barouch,
Beth Israel Deaconess Medical Center, USA
Short Talk: Prospects for Monoclonal Antibody Therapy for HIV-1
Short Talk: Prospects for Monoclonal Antibody Therapy for HIV-1
Devin Sok,
International AIDS Vaccine Initiative, USA
Short Talk: Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Facilitates Broader Neutralization of HIV
Short Talk: Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Facilitates Broader Neutralization of HIV
08:00—11:15
Host-Virus Interactions and Responses
*
Paul R. Clapham,
University of Massachusetts Medical School, USA
*
Jaisri R. Lingappa,
University of Washington, USA
Michael Emerman,
Fred Hutchinson Cancer Research Center, USA
How Ancient Host-Virus Interactions Shaped the Modern HIV-1 Pandemic in Humans
How Ancient Host-Virus Interactions Shaped the Modern HIV-1 Pandemic in Humans
Theodora Hatziioannou,
Aaron Diamond AIDS Research Center (ADARC), USA
Restriction Factors and the Adaptation of HIV-1 to Non-Human Primates
Restriction Factors and the Adaptation of HIV-1 to Non-Human Primates
Andrea Cimarelli,
CIRI, International Center for Infectology Research, France
Exploring the Multiple Layers of Complexity Existing during the Early Phases of Infection of Myeloid Cells by Primate Lentiviruses
Exploring the Multiple Layers of Complexity Existing during the Early Phases of Infection of Myeloid Cells by Primate Lentiviruses
Reuben S. Harris,
University of Minnesota, USA
Natural Resistance to HIV Infection by Select APOBEC3H Haplotypes
Natural Resistance to HIV Infection by Select APOBEC3H Haplotypes
Daniel Claiborne,
Ragon Institute of MGH, MIT, and Harvard, USA
Short Talk: Protective HLA Alleles Reduce Markers of Gut Damage and Microbial Translocation and Influence Early Inflammatory Cytokine Profiles
Short Talk: Protective HLA Alleles Reduce Markers of Gut Damage and Microbial Translocation and Influence Early Inflammatory Cytokine Profiles
Rui Andre Raposo,
George Washington University, USA
Short Talk: Increased Expression of Host Restriction Factors in HLA-B*57+ Individuals
Short Talk: Increased Expression of Host Restriction Factors in HLA-B*57+ Individuals
08:00—11:15
Novel Mechanisms for Vaccine-Induced Protection
*
Genoveffa Franchini,
NCI, National Institutes of Health, USA
*
Jeffrey Robert Schneider,
Northwestern University, USA
Silke Paust,
Baylor College of Medicine, USA
NK Memory to Experimental HIV Vaccines in Mice and Humanized Mice
NK Memory to Experimental HIV Vaccines in Mice and Humanized Mice
Galit Alter,
MIT and Harvard University, USA
Fc-Signatures of Functional HIV-Specific Antibodies
Fc-Signatures of Functional HIV-Specific Antibodies
Penny L. Moore,
University of the Witwatersrand and National Institute for Communicable Diseases, South Africa
Evolution of V1V2 Broad Neutralizing Antibodies during HIV-1 Infection
Evolution of V1V2 Broad Neutralizing Antibodies during HIV-1 Infection
Louis J. Picker,
Oregon Health & Science University, USA
Effector Memory T-Cell Targeted Vaccines
Effector Memory T-Cell Targeted Vaccines
Susan Johnson,
US Military HIV Research Program, USA
Short Talk: HIV-Specific Cytolytic CD4 T Cells Are Distinct from Th1 Cells and Preserved in HIV Infection
Short Talk: HIV-Specific Cytolytic CD4 T Cells Are Distinct from Th1 Cells and Preserved in HIV Infection
Anna Aldovini,
Boston Children's Hospital and Harvard Medical School, USA
Short Talk: Resistance to Infection, Early and Persistent Suppression of SIVmac251 Viremia and Significant Reduction of Tissue Viral Burden after Mucosal Vaccination in Females Rhesus macaques
Short Talk: Resistance to Infection, Early and Persistent Suppression of SIVmac251 Viremia and Significant Reduction of Tissue Viral Burden after Mucosal Vaccination in Females Rhesus macaques
11:15—12:45
Hands-On Computer Session on Los Alamos HIV Sequence Database
Maximum attendance: 60. Interested participants may sign up at the meeting on a first-come, first-serve basis.
*
Brian T. Foley,
Los Alamos National Lab, USA
*
Bette Tina Marie Korber,
Los Alamos National Laboratory, USA
*
Will Fischer,
Los Alamos National Laboratory, USA
14:30—16:30
Panel 2: Functions of Protective Antibodies
Stephen J. Kent,
University of Melbourne, Australia
Margaret E. Ackerman,
Dartmouth College, USA
Nancy L. Haigwood,
Oregon Health & Science University, USA
Ruth M. Ruprecht,
Texas Biomedical Research Institute, USA
James Arthos,
NIAID, National Institutes of Health, USA
*
Susan Zolla-Pazner,
Icahn School of Medicine at Mount Sinai, USA
14:30—16:30
Workshop 2: It Is All in the Head: HIV, Macs, DCs and the CNS
*
Brenda L. Fredericksen,
NIAID, National Institutes of Health, USA
*
Pamela J. Skinner,
University of Minnesota, USA
Joe Casazza,
NIAID, National Institutes of Health, USA
Identification of HIV-Infected CD4+ T Cells using HIV RNA and Broadly Neutralizing Antibodies
Identification of HIV-Infected CD4+ T Cells using HIV RNA and Broadly Neutralizing Antibodies
Andrew N. Harman,
Westmead Institute, Australia
The Role of Mucosal Dendritic Cells in HIV Infection
The Role of Mucosal Dendritic Cells in HIV Infection
Rosa Camacho,
Instituto Nacional de Enfermedades Respiratorias, Mexico
TNFalpha Overproduction by Conventional Dendritic Cells in Viremic versus Controller HIV Subjects
TNFalpha Overproduction by Conventional Dendritic Cells in Viremic versus Controller HIV Subjects
Alexandre Deshiere,
Laval University, Canada
Transcriptomic and Proteomic Screening of Host Genes Modulated by HIV-1 in Human Macrophages: A Highly Sensitive Strategy for the Identification of New Susceptibility/Restriction Factors
Transcriptomic and Proteomic Screening of Host Genes Modulated by HIV-1 in Human Macrophages: A Highly Sensitive Strategy for the Identification of New Susceptibility/Restriction Factors
Katharina Borm,
Burnet Institute, Australia
Envelope Glycoprotein Determinants of Macrophages Tropism during Progressive HIV-1 Subtype C Infection
Envelope Glycoprotein Determinants of Macrophages Tropism during Progressive HIV-1 Subtype C Infection
Maria Paz Gonzalez-Perez,
UMASS, USA
HIV-1 R5 Envelopes from Brain and Immune Tissue of AIDS Patients with Normal Neurology are Less Functional and Less Macrophage-Tropic Compared to those in HAD Patients
HIV-1 R5 Envelopes from Brain and Immune Tissue of AIDS Patients with Normal Neurology are Less Functional and Less Macrophage-Tropic Compared to those in HAD Patients
Sheila M. Keating,
GigaGen, USA
Cerebrospinal Fluid and Blood Inflammatory Biomarkers are Differentially Elevated in HIV and Neurological Disease
Cerebrospinal Fluid and Blood Inflammatory Biomarkers are Differentially Elevated in HIV and Neurological Disease
David R. Graham,
Johns Hopkins School of Medicine, USA
A Combined Proteomics and Metabolomics Study of CSF from HAND Patients Under cART Therapy Reveals Evidence for Ongoing Macrophage Activation and Pertubations in Glutamate Metabolism
A Combined Proteomics and Metabolomics Study of CSF from HAND Patients Under cART Therapy Reveals Evidence for Ongoing Macrophage Activation and Pertubations in Glutamate Metabolism
15:30—17:00
Keystone Symposia Webcast - HIV/AIDS: Strategies for an Endgame
Taped rebroadcast of the first virtual Keystone Symposia event. This can also be viewed online at any time at www.visualwebcaster.com/KSHIV.
17:00—19:15
HIV, the Microbiome and the Mucosa
*
Charles R. Rinaldo,
University of Pittsburgh, USA
*
John C. Tilton,
Case Western Reserve University, USA
Dan R. Littman,
HHMI/New York University School of Medicine, USA
Immue Homeostasis and Commensal Bacteria
Immue Homeostasis and Commensal Bacteria
Nichole R. Klatt,
University of Miami, USA
Kinetics of Mucosal Dysfunction after SIV Infection of Rhesus macaques
Kinetics of Mucosal Dysfunction after SIV Infection of Rhesus macaques
Satya Dandekar,
University of California, Davis, USA
HIV Pathogenesis: The GALT
HIV Pathogenesis: The GALT
Brent E. Palmer,
University of Colorado Health Sciences Center, USA
Short Talk: Alterations in the Gut Microbiota Associated with HIV Infection
Short Talk: Alterations in the Gut Microbiota Associated with HIV Infection
Hannah J. Barbian,
University of Pennsylvania, USA
Short Talk: Evaluating the Enteric Virome as a Marker of Disease Progression in SIVcpz Infected Wild-Living Chimpanzees
Short Talk: Evaluating the Enteric Virome as a Marker of Disease Progression in SIVcpz Infected Wild-Living Chimpanzees
17:00—19:15
Engineering Protective Immune Responses
*
Rena D. Astronomo,
Fred Hutchinson Cancer Research Center, USA
*
Mark Connors,
NIAID, National Institutes of Health, USA
William Schief,
International AIDS Vaccine Initiative and The Scripps Research Institute, USA
Vaccines to Induce Broadly Neutralizing Antibodies
Vaccines to Induce Broadly Neutralizing Antibodies
Nicholas M. Valiante,
Novartis Vaccines and Diagnostics, USA
Minimal Essential Adjuvants: A Rational Approach for Optimizing Small Molecules as Vaccine Adjuvants
Minimal Essential Adjuvants: A Rational Approach for Optimizing Small Molecules as Vaccine Adjuvants
Mario Roederer,
NIAID, National Institutes of Health, USA
Antigenic Heterogeneity of Clonal Envelopes: A Novel Immune Evasion Mechanism
Antigenic Heterogeneity of Clonal Envelopes: A Novel Immune Evasion Mechanism
Louise Scharf,
California Institute of Technology, USA
Short Talk: A New Site of Broad Vulnerability on the HIV-1 Envelope Spike Defined by a Patient-Derived Antibody
Short Talk: A New Site of Broad Vulnerability on the HIV-1 Envelope Spike Defined by a Patient-Derived Antibody
08:00—11:15
Reservoirs, Latency, Reactivation and Eradication
*
Robert W. Buckheit, Jr.,
ImQuest BioSciences, Inc., USA
*
Linda Chelico,
University of Saskatchewan, Canada
Daria J. Hazuda,
Merck Research Laboratories, USA
New Drug Targets in the Search for an HIV Cure
New Drug Targets in the Search for an HIV Cure
Hiroyu Hatano,
University of California, San Francisco, USA
HIV Persistence in "Elite" Controllers
HIV Persistence in "Elite" Controllers
Steven Wolinsky,
Northwestern University, USA
Persistent HIV-1 Replication and Evolution in Drug Sanctuaries within Peripheral Lymphoid Organ Compartments in Patients on Combination Antiretroviral Therapy
Persistent HIV-1 Replication and Evolution in Drug Sanctuaries within Peripheral Lymphoid Organ Compartments in Patients on Combination Antiretroviral Therapy
Edward A. Berger,
NIAID, National Institutes of Health, USA
Short Talk: Novel CD4-Based Chimeric Antigen Receptors: Toward an HIV Functional Cure Using Genetically Modified CD8+ T Cells
Short Talk: Novel CD4-Based Chimeric Antigen Receptors: Toward an HIV Functional Cure Using Genetically Modified CD8+ T Cells
Scott G. Kitchen,
University of California, Los Angeles AIDS Institute, USA
Short Talk: Engineering Stem Cells with Chimeric Antigen Receptors for HIV-Specific T Cell Immunity
Short Talk: Engineering Stem Cells with Chimeric Antigen Receptors for HIV-Specific T Cell Immunity
08:00—11:15
From Concepts to Implementation
*
Liang Shang,
University of Minnesota, USA
*
William A. Paxton,
Institute of Infection and Global Health, UK
Nicole Frahm,
Bill & Melinda Gates Medical Research Institute, USA
Immunogenicity of HIV Vaccine Candidates in the HIV Vaccine Trials Network (HVTN)
Immunogenicity of HIV Vaccine Candidates in the HIV Vaccine Trials Network (HVTN)
Magdalena E. Sobieszczyk,
Columbia University, USA
Lessons from HVTN 505 Efficacy Trial of a DNA/rAd5 HIV Preventive Vaccine
Lessons from HVTN 505 Efficacy Trial of a DNA/rAd5 HIV Preventive Vaccine
Jerome H. Kim,
International Vaccine Institute, South Korea
RV144 and HIV Acquisition: Insights and New Questions
RV144 and HIV Acquisition: Insights and New Questions
Thomas C. Quinn,
NIAID and Johns Hopkins University, USA
The Impact of Combination Prevention on the HIV Pandemic
The Impact of Combination Prevention on the HIV Pandemic
Susan Zolla-Pazner,
Icahn School of Medicine at Mount Sinai, USA
Short Talk: IgG V3-Specific Antibody (Ab) Reactivity in Plasma from RV144: Implications for Vaccine Efficacy
Short Talk: IgG V3-Specific Antibody (Ab) Reactivity in Plasma from RV144: Implications for Vaccine Efficacy
Iskra Tuero,
Universidad Peruana Cayetano Heredia, Peru
Short Talk: SIV Trimeric versus Monomeric Env-Induced Antibodies and Delayed SIV Acquisition in Vaccinated Female Rhesus macaques
Short Talk: SIV Trimeric versus Monomeric Env-Induced Antibodies and Delayed SIV Acquisition in Vaccinated Female Rhesus macaques
11:15—12:45
Hands-On Computer Session on Los Alamos HIV Immunology Database
Maximum attendance: 60. Interested participants may sign up at the meeting on a first-come, first-serve basis.
*
Brian T. Foley,
Los Alamos National Lab, USA
*
Bette Tina Marie Korber,
Los Alamos National Laboratory, USA
*
Will Fischer,
Los Alamos National Laboratory, USA
14:30—16:30
Panel 3: Triggering Protective B-Cell Responses
*
George K. Lewis,
University of Maryland, USA
M. Anthony Moody,
Duke University Medical Center, USA
Rogier W. Sanders,
University of Amsterdam and Weill Cornell Medical College, Netherlands
Neutralizing Antibodies Induced by a Soluble Cleaved HIV Envelope Trimer, BG505 SOSIP.664 gp140
Neutralizing Antibodies Induced by a Soluble Cleaved HIV Envelope Trimer, BG505 SOSIP.664 gp140
Jens P. Wrammert,
Emory University, USA
Interrogating SIV/HIV Specific Plasmablast Responses in Rhesus macaques
Interrogating SIV/HIV Specific Plasmablast Responses in Rhesus macaques
Alejandro Balazs,
Massachusetts General Hospital, USA
Burton E. Barnett,
Genomics Institute of the Novartis Research Foundation, USA
15:30—17:00
Keystone Symposia Webcast - HIV/AIDS: Strategies for an Endgame
Taped rebroadcast of the first virtual Keystone Symposia event. This can also be viewed online at any time at www.visualwebcaster.com/KSHIV.
17:00—18:45
Cellular and Genetic Therapies for HIV/AIDS (Joint)
*
Nicole Frahm,
Bill & Melinda Gates Medical Research Institute, USA
*
J. Victor Garcia-Martinez,
University of North Carolina at Chapel Hill, USA
Robert F. Siliciano,
Johns Hopkins University School of Medicine, USA
Prospects for HIV Eradication
Prospects for HIV Eradication
Nicolas Chomont,
Université de Montréal, Canada
HIV Persistence during ART: What Can We Learn from CD4 T Cell Homeostasis?
HIV Persistence during ART: What Can We Learn from CD4 T Cell Homeostasis?
Jerome A. Zack,
University of California, Los Angeles, USA
Novel Means for Eliminating Latent HIV Reservoirs
Novel Means for Eliminating Latent HIV Reservoirs
18:45—19:30
Keynote Address (Joint)
Mark M. Davis,
Stanford University School of Medicine, USA
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
![]() |
![]() |
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
![]() |
|
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
![]() |
|
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |